Douglass Drelich, MD
Hematology · Philadelphia, PANPI 1932394095
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), food and beverage and education — rather than concentrated in one kind of arrangement. CSL Behring accounts for 71.8% of it on its own, with 4 other manufacturers making up the rest. 2023 is the largest year on record at $560, 3.6 times the $154 reported in 2019. That places this record below the midpoint for hematology clinicians in PA, where the typical reported total is $1,542.
Across 6 payments — averaging $159.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$685
- AstraZeneca$123
- Sanofi$117
- Aptevo Therapeutics Inc$17
- Pfizer$13
Across 17 payments — averaging $5652.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spark Therapeutics, Inc.$96K
What the payments were for
- Speaking & faculty fees$56059%
- Food & beverage$36538%
- Education$293%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 2 | $685 |
| AstraZeneca | 1 | $123 |
| Sanofi | 1 | $117 |
| Aptevo Therapeutics Inc | 1 | $17 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$955 in reported general payments places this provider in the 45th percentile of 64 hematology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 11 | $273 |
| Warfarin Sodium | 20 | $163 |
Paid to pharmacies, not to this prescriber.
Other hematology in Philadelphia
- Selina LugerPhiladelphia$122K
- Scott DessainPhiladelphia$79K
- Dan VoglPhiladelphia$79K
- Edward StadtmauerPhiladelphia$72K
- Sanaa RizkPhiladelphia$55K
- Douglas CinesPhiladelphia$44K
- Adam CukerPhiladelphia$38K
- Ralph VassalloPhiladelphia$32K
- Elizabeth HexnerPhiladelphia$23K
- Scott PeslakPhiladelphia$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.